These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28363997)

  • 1. Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy.
    Li D; Bentley C; Anderson A; Wiblin S; Cleary KLS; Koustoulidou S; Hassanali T; Yates J; Greig J; Nordkamp MO; Trenevska I; Ternette N; Kessler BM; Cornelissen B; Cragg MS; Banham AH
    Cancer Res; 2017 May; 77(10):2699-2711. PubMed ID: 28363997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A*0201.
    Trenevska I; Anderson AP; Bentley C; Hassanali T; Wiblin S; Maguire S; Pezzella F; Banham AH; Li D
    PLoS One; 2021; 16(4):e0249967. PubMed ID: 33836029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.
    Barfoed AM; Petersen TR; Kirkin AF; Thor Straten P; Claesson MH; Zeuthen J
    Scand J Immunol; 2000 Feb; 51(2):128-33. PubMed ID: 10652158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.
    Veomett N; Dao T; Liu H; Xiang J; Pankov D; Dubrovsky L; Whitten JA; Park SM; Korontsvit T; Zakhaleva V; Casey E; Curcio M; Kharas MG; O'Reilly RJ; Liu C; Scheinberg DA
    Clin Cancer Res; 2014 Aug; 20(15):4036-46. PubMed ID: 24850840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
    Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
    Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
    Ahmed M; Lopez-Albaitero A; Pankov D; Santich BH; Liu H; Yan S; Xiang J; Wang P; Hasan AN; Selvakumar A; O'Reilly RJ; Liu C; Cheung NV
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen.
    Low L; Goh A; Koh J; Lim S; Wang CI
    Nat Commun; 2019 Nov; 10(1):5382. PubMed ID: 31772160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
    Hoffmann TK; Loftus DJ; Nakano K; Maeurer MJ; Chikamatsu K; Appella E; Whiteside TL; DeLeo AB
    J Immunol; 2002 Feb; 168(3):1338-47. PubMed ID: 11801674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
    J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
    Wittman VP; Woodburn D; Nguyen T; Neethling FA; Wright S; Weidanz JA
    J Immunol; 2006 Sep; 177(6):4187-95. PubMed ID: 16951384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
    Denkberg G; Klechevsky E; Reiter Y
    J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and evaluation of cancer binding capacity of HLA-A2-WT1 complex-targeting antibody.
    Yao X; Matosevic S
    Immunol Lett; 2024 Aug; 268():106881. PubMed ID: 38810886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity.
    Card KF; Price-Schiavi SA; Liu B; Thomson E; Nieves E; Belmont H; Builes J; Jiao JA; Hernandez J; Weidanz J; Sherman L; Francis JL; Amirkhosravi A; Wong HC
    Cancer Immunol Immunother; 2004 Apr; 53(4):345-57. PubMed ID: 14610621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
    Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
    J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
    Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties.
    Verma B; Hawkins OE; Neethling FA; Caseltine SL; Largo SR; Hildebrand WH; Weidanz JA
    Cancer Immunol Immunother; 2010 Apr; 59(4):563-73. PubMed ID: 19779714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
    Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
    Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
    Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
    Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
    Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
    J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.